Пероральная дастаўка пептыдаў: Здзелка Novo GLP-1/GIP на 300 мільёнаў долараў

What Oral Peptide Delivery Changes in the Design Brief

Oral peptide delivery changes the design objective itself. Instead of optimising potency first and formulating later, the sequence and the delivery strategy have to be co-designed from the start, because the molecule now has to survive the gut before it can ever reach its receptor. Frontiers’ review of the pharmacokinetic boundaries of oral peptide dosing, published on 20 March 2026, frames the requirement as four survival conditions the peptide must satisfy at once: it must withstand gastric acid and proteases, resist aggregation, retain potency after modification, and carry a half-life long enough to compensate for a sub-1% absorbed dose.

That is a different brief from an injectable. An injected peptide bypasses the gastrointestinal tract entirely, so potency and half-life are the whole problem. An oral candidate carries those same requirements plus a delivery gauntlet, and the four conditions compete with each other: the modifications that improve protease resistance often work against permeability, and the ones that improve permeability often cost potency.

The Novo Nordisk and Hengrui Pharma licence for HRS-1596, announced on 29 верасень 2026, is worth reading in that light. The disclosed terms are $300 million upfront, up to $2.6 billion in total potential value, plus royalties on net sales. The asset is a once-weekly oral GLP-1/GIP dual receptor agonist. What is being licensed is not only a molecule but a delivery problem that has been solved far enough to justify a Phase I programme.

⚠️ Папярэджанне: HRS-1596 is disclosed as a once-weekly oral GLP-1/GIP dual receptor agonist. This article discusses research-stage and clinical-stage peptide development, не медыцынская парада. Consult a qualified professional before making any medical decision.

Why Oral Peptide Delivery Is Hard: The Three Barriers

An oral peptide has to survive three separate barriers before it reaches the bloodstream: enzymatic breakdown in the gut lumen, the epithelial cell layer, and the mucus layer coating the intestinal wall. Each one fails for a different reason, and each responds to a different design or formulation lever, which is why no single modification makes a peptide orally available.

The first barrier is chemical. Digestive proteases in the stomach and small intestine cleave the peptide backbone before absorption is even possible. An early screen of 17 peptides in simulated GI fluids found that enzymatic degradation, not pH, drove most of the loss, with cyclosporin, octreotide and desmopressin the notable exceptions (Molecular Pharmaceutics, 2015). That is a single-study result from one assay set, but it points designers toward backbone stabilization rather than enteric coating alone.

The second and third barriers are physical. А 2022 review of permeation-enhancer strategies describes permeability as a three-layer problem: luminal enzymes, the epithelial barrier with its paracellular, transcellular and carrier-mediated routes, and the mucus layer. The same review explains why permeation enhancers deliver only transient gains: they act locally, are payload-specific, and run into safety and tolerability limits at the doses needed.

That split matters for the intestinal permeability of peptides. Enzyme resistance, epithelial transport and mucus penetration each need their own fix, so oral programs are judged on the combination, not on any one modification.

Peptide Sequence Design for Oral Delivery

Oral delivery changes the design brief: sequence and modification choices must now serve stability and half-life, not potency alone. A peptide that loses its receptor affinity is useless, but one that is degraded before it reaches the intestinal wall never gets the chance to bind.

The standard chemical strategies for oral peptides are cyclization, D-amino acid substitution, other non-natural residues including N-methylation, lipidation or acylation, PEGylation and glycosylation. More rigid structures are generally less vulnerable to protease attack, як peer-reviewed reviews of cyclic peptides and oral delivery barriers describe. Cyclization buys conformational rigidity and some protease resistance; it does not by itself solve permeability.

Semaglutide shows how the two pillars combine. MOL Changes’ analysis of the oral GLP-1 development brief notes that the molecule pairs an Aib substitution at position 8, which blocks DPP-4 cleavage, with a Lys26 gamma-Glu-OEG2 spacer to a C18 di-acid for albumin binding: enzyme resistance plus half-life extension.

That second pillar carries a cost. Hydrophobic modifications that extend half-life, such as C18 di-acid acylation, lower aqueous solubility and raise aggregation tendency, звужэнне практычнага акна фармулёўкі. Sequence decisions made at discovery therefore set the ceiling for everything downstream.

Stability Testing That Reflects the Gastrointestinal Tract

Oral peptide stability testing asks whether the peptide survives transit, not whether it survives storage. The developability assessment a peptide programme runs for an oral candidate is a GI-exposure programme: simulated gastric fluid and fasted-state simulated intestinal fluid, with and without enzymes, acid exposure, and precipitation risk as pH shifts from stomach to intestine (Bak et al., 2015). Injectable programmes target something else entirely, namely solution and shelf stability, агрэгацыя, акісленне, deamidation and container-closure compatibility.

The biorelevant stability toolkit at discovery stage is well defined. Simulated gastric fluid sits at roughly pH 1.2 з пепсін; fasted-state simulated intestinal fluid adds pancreatin; incubation runs at 37 °C з выбаркай па часе; reversed-phase HPLC tracks intact peptide while LC-MS identifies fragments. Enzyme-free controls separate pH-driven hydrolysis from proteolysis.

Для падказкі: Run the enzyme-free control alongside every enzyme-containing sample. Без гэтага, a loss of intact peptide cannot be attributed to proteolysis rather than acid hydrolysis, and the mechanism you need for redesign stays hidden.

That distinction carries the practical consequence. A programme that runs only shelf-life stability will not see the failure mode that eliminates oral candidates, because degradation in the gut happens on a timescale and through chemistry that storage studies never probe.

Intestinal Permeability and the Limits of Permeation Enhancement

Permeation enhancers raise the intestinal permeability of peptides at the margin, but they do not remove the ceiling. А 2026 review of oral peptide delivery complexity reports that most therapeutic peptides show oral bioavailability below 1%, describing this as the “low inherent oral bioavailability (<1%) observed for most compounds” (Oral peptide delivery complexity review, ЧВК, 2026-03-24). That figure is the baseline every oral program is working against.

Oral semaglutide shows what the best-characterised enhancer can achieve. Its absolute bioavailability is approximately 0.4% каб 1% under strict fasting conditions, and near zero when taken with food, per a 2026 Frontiers review of oral peptide pharmacokinetic boundaries reporting the FDA clinical pharmacology review (Межы ў дастаўцы лекаў, 2026-03-20). The fasting requirement is not a labelling quirk; it is the mechanism showing through.

How SNAC actually helps semaglutide cross the membrane is more specific than a lipophilicity boost. Work published in Камунікацыі прыроды in October 2025 found that SNAC forms permeation-enhancer-filled fluid membrane defects, helps monomerise semaglutide in the water layer, then neutralises to insert into the bilayer, lowering aqueous free energy by about 1 kcal/mol versus a fixed protonation state. The effect is transient, local, and tied to that payload.

Higher numbers exist, and they are outliers rather than a template. The Luna18 preclinical outlier, a cyclic peptide from Chugai, reaches 21% каб 47% oral bioavailability in preclinical models, and the MEDI7219 dog study, an AstraZeneca enteric-coated tablet, reached approximately 6% in dogs, about a five-fold increase over semaglutide formulated with SNAC (PMC complexity review, 2026-03-24). The review presents MEDI7219 as a cross-compound comparison, not a head-to-head trial, so treat the multiple as directional.

Пептыд 1 Why formulation alone rarely clears the low single-digit ceiling comes down to the excipient toolkit. Formulation efforts have relied on a small set of well-characterised excipients, “rarely yielding bioavailability’s beyond the low single-digit range in large animals and humans”; what enabled efficacy at low single-digit bioavailability in oral semaglutide, MK-0616 and icotrokinra was structural modification (PMC complexity review, 2026-03-24). Enhancers also carry a dose-limiting constraint: they act by disrupting the membrane, so safety and tolerability at the doses needed for absorption set a practical ceiling that varies by payload.

Formulation Screening and the Developability Gate

Formulation screening for an oral peptide is a staged elimination process, not an excipient search. The formulation screening funnel runs excipient compatibility and stability screening first, then function-based multi-excipient selection, enteric protection so release happens after the stomach, permeation-enhancer screening, and dose-loading feasibility, before any candidate reaches biorelevant release testing (PMC and Bak et al., 2015). Each stage exists to remove candidates cheaply, and constrained loading is a hard design limit: helper excipients compete with the peptide for space in the dosage form, so every added functional excipient takes room the dose needs.

Solid State Peptide Synthesis Potency and half-life are entry criteria for the oral route, not downstream properties. The potency gate for oral candidates is a low-nanomolar EC50, because low potency cannot achieve efficacy at a sub-1% absorbed dose (Frontiers, 2026). The half-life gate for once-daily oral dosing sets approximately 24 hours or more as the practical minimum when bioavailability sits below 1%; 12 каб 24 hours stays viable only with twice-daily dosing or compensating potency and therapeutic window (Frontiers, 2026).

Практычныя наступствы: a program that cannot clear the potency and half-life gates at discovery rarely recovers them Liberty Blue Peptide Synthesizer later, so both belong in the candidate-selection brief alongside peptide stability testing and the permeability plan.

Analytical Characterization for Oral Programs

Oral programs must add biorelevant-medium degradant profiling to standard release testing. An analytical package built for an injectable will not characterize the degradants an oral program actually produces.

That means three additions. Першы, sequence and modification integrity: confirming the backbone and any non-natural residues survived synthesis intact. Па-другое, degradation-product identification in simulated gastric and intestinal media, not just in buffer. Трэці, counterion and salt-form characterization, since trifluoroacetate exchange affects both assay accuracy and tolerability. Endotoxin testing by LAL assay and a complete certificate of analysis belong in the same package, і ISO 13485 або ISO 9001 context tells you whether the supplier’s quality system can support it.

Methods must be validated against the validation characteristics Q2(R2) sets out, published by the FDA in March 2024. Read those as expectations rather than thresholds: the guideline gives signal-to-noise guidance of roughly 3:1 for detection limit and at least 10:1 for quantitation limit, not peptide-specific cutoffs.

Ключ на вынас: A validated peptide analytical characterization package should cover specificity and selectivity, дакладнасць, дакладнасць Пептыд 2 including repeatability and intermediate precision, дыяпазон, response and linearity, detection and quantitation limits, and robustness.

This is where a research-grade supplier stops being enough. А 95% purity floor is a conventional research-grade baseline, but it says nothing about which degradants are present or whether the method that measured it was validated for an oral matrix.

Discovery-Stage Synthesis Needs Versus Development and Scale-Up

Discovery and development optimise for different things. Discovery optimises for learning: many analogues, milligram to small research quantities, screening-grade purity acceptable, and turnaround valued over process optimisation. Development optimises for dependable manufacturing: fewer routes, locked and transferable processes, tight impurity control, lot-to-lot comparability, gram-to-kilogram supply, and full analytical and regulatory documentation. The change of optimisation target at scale-up, not the batch size alone, is what breaks programs, as the discovery-to-development framing in Bak et al.’s developability primer sets out (2015).

Peptide scale-up failure modes concentrate in incomplete coupling and deprotection, aggregation and poor resin swelling or mass transfer, thermal gradients, and purification bottlenecks. Small inefficiencies compound across every amino-acid addition, so yield and purity loss from milligram to kilogram scale is real but not reported as a percentage in any primary source, which is why it is described here rather than quantified.

Ключ на вынас: Choose your synthesis partner by the stage you are entering, not the stage you are in. A route that tolerates screening-grade purity at milligram scale will not carry a program into gram-to-kilogram supply without process lock and full documentation.

MOL Changes runs custom peptide synthesis from milligram to kilogram scale, with sequences up to 200 amino acids and support for 300-plus modifications, and purity from crude through 99 percent. Quality-control methods available include HPLC, LC-MS, даследаванне эндатаксінаў, and sterility testing in a Class 100 чыстае памяшканне.

Common Misconceptions About Oral Peptide Delivery

Four beliefs cause most of the expensive failures in oral peptide programs: that a permeation enhancer solves absorption, that oral delivery is a formulation problem rather than a molecule problem, that a stable peptide is a shelf-stable peptide, and that scale-up is simply a bigger batch.

The first two are related. Enhancers act transiently and locally at the intestinal wall, so they widen a window rather than remove the barrier. What changed the outlook for oral peptides was structural modification, which is why formulation alone rarely clears the low single-digit bioavailability ceiling that oral programs run into. If your team is screening excipients before the sequence has been optimised for the gut, the screening is premature.

The third misconception confuses two different measurements. Resistance to gastrointestinal exposure and shelf-life stability are separate properties, and a peptide that survives twelve months on a shelf may still be degraded before it reaches an absorptive surface.

The fourth is a change of target, not of volume. Scale-up shifts what you are optimising for, so a route that works at milligram scale can fail on the parameters that matter later.

⚠️ Папярэджанне: Oral bioavailability for peptides remains low and variable. No single modification or excipient resolves intestinal permeability. HRS-1596 is an early-stage candidate, and nothing here is an efficacy, safety, or approval claim.

Часта задаюць пытанні

What oral bioavailability does a peptide need to be worth developing?

There is no single threshold, because the half-life and potency gates interact. A modelling analysis reported in Frontiers in Drug Delivery found that a peptide with a half-life of roughly 24 hours or longer can accumulate meaningfully even at sub-1% bioavailability, while the same analysis places the practical potency ceiling at low-nanomolar EC50. Oral viability is a property of the molecule’s pharmacokinetic profile, not of the delivery technology alone.

Why must oral semaglutide be taken on an empty stomach?

Because absorption collapses when food is present. The fasting requirement for oral semaglutide reflects an absolute bioavailability of approximately 0.4-1% under strict fasting conditions, with no more than 4 oz of water, an empty stomach, and a 30-minute fast after dosing, and near-zero absorption with food, as recorded in the FDA clinical pharmacology review and reported in a Frontiers in Drug Delivery review. The instruction is the difference between a therapeutic dose and an ineffective one.

Can permeation enhancers make any peptide orally available?

няма. Enhancers such as SNAC work by creating transient defects in the intestinal membrane that let the co-formulated peptide cross, and that mechanism is local, short-lived, and payload-specific. An enhancer that carries one peptide across the epithelium will not necessarily carry another, and raising the dose runs into gastrointestinal tolerability limits. Permeation enhancement widens the window for a candidate that already has the right potency and half-life; it does not make an arbitrary peptide absorbable.

What stability testing does an oral peptide program need that an injectable program does not?

An oral program needs stability data generated in gastrointestinal-relevant media, not just in buffer. Injectable programs characterise the peptide in formulation buffer and plasma; oral candidates additionally have to survive gastric acid, pepsin, and intestinal proteases, so peptide stability testing has to model those conditions rather than assume them. That means proteolytic stability assays in simulated gastric and intestinal fluid, and release methods that reflect the intestinal environment the capsule actually encounters.

How do discovery-stage and development-stage purity requirements differ?

Discovery work tolerates crude to 95% чысціня, because the question being asked is whether the sequence behaves, not whether it can be filed. Development and scale-up work moves toward 99% purity with a documented analytical package, since the same material has to support toxicology, clinical supply, і нарматыўны агляд. A sequence that looks clean at research grade can reveal impurity and stability problems once the purity floor rises.

What does the Novo and Hengrui deal actually signal?

It signals that large pharmaceutical companies are willing to pay for oral peptide delivery capability rather than build it. Hengrui’s announcement of the HRS-1596 licence disclosed a deal worth up to approximately $300 million for an oral GLP-1/GIP candidate, with Novo Nordisk taking the development forward. The signal for anyone running an oral program is the structure rather than the headline number: the licensor retained the discovery and early development work, and the partner bought the later-stage capability.

Выснова і наступныя крокі

Oral peptide delivery moves five decisions earlier and makes them interdependent: sequence design, тэставанне стабільнасці, permeability strategy, formulation screening and analytical characterization. Change one and the others move with it, which is why the evaluation sequence matters more than any single modification. A candidate that survives fasted-state intestinal media but fails the developability gate is not a near-miss; it is a program that needed the permeability question answered before the synthesis scale changed.

That is also where the stage distinction earns its keep. Discovery work tolerates crude material and rapid iteration, while development and peptide scale-up demand documented purity, validated methods and batch-to-batch consistency. The handoff points between those stages, not the individual steps, are where programs lose time.

The HRS-1596 licence announced on 29 верасень 2026 is one signal in a broader shift: delivery capability, not receptor potency alone, is becoming the differentiator. HRS-1596 is disclosed as phase I-ready for once-weekly oral dosing, and no efficacy or approval claim follows from that disclosure. Oral bioavailability remains low and variable, and no single modification or excipient resolves permeability on its own.

If you are scoping an oral candidate, the useful next step is a capability conversation: talk to an expert about which stage your sequence sits at and what the data package needs to show.

Раскрыццё інфармацыі: MOL Changes provides custom peptide synthesis services. This article discusses research-stage and clinical-stage peptide development and is not medical advice; consult a qualified professional before making medical decisions.